VEGFA and Pleural effusion: Of note, some MET-related AEs, such as pleural effusion and increased creatinine, have not been reported with amivantamab.43 Pleural effusion is reported in 8% of patients treated with tepotinib,77 and increased creatinine is reported in 19% of patients treated with capmatinib and 18% of patients treated with tepotinib.43 Although the cause of MET-associated AEs is not clearly identified, some may occur due to the role of MET in regulating vascular endothelial permeability43; thus, vascular endothelial growth factor inhibitors are currently being investigated.